This photomicrograph reveals Mycobacterium tuberculosis bacteria using acid-fast Ziehl-Neelsen stain; Magnified 1000 X. The acid-fast stains depend on the ability of mycobacteria to retain dye when treated with mineral acid or an acid-alcohol solution such as the Ziehl-Neelsen, or the Kinyoun stains that are carbolfuchsin methods specific for M. tuberculosis. Credit: public domain
Drug-resistant tuberculosis is a major health challenge across much of Africa, but a new medicine being pioneered in South Africa could be a breakthrough after decades of frustration.
Bedaquiline is being made available to 3,000 people suffering side effects of the usual drug-resistant tuberculosis treatment, or who have developed complete drug resistance.
The early signs are encouraging, doctors say, though bedaquiline hasn't yet been tested in large-scale clinical trials.
The new drug—one of the first new tuberculosis antibiotics released in 40 years—was first given to 217 South African patients as part of an early access programme.
Jennifer Hughes, a 36-year-old British doctor in Cape Town, said she has seen the benefits.
Already, word has spread at Hughes's clinic in Khayelitsha, a poor township, and people are coming from all over the city requesting the new drug, developed by US-based pharmaceutical company Janssen.
"Everyone has heard that this is where you get better treatment," said Hughes, who recalls the "really, really happy day" when her first bedaquiline patient was declared tuberculosis-free in November last year.
South Africa has one of the worst tuberculosis epidemics in the world, with more than 1,000 cases per 100,000 people and the department of health describing the rise of drug-resistant tuberculosis as a "major public health problem."
"We want to get 3,000 patients on bedaquiline this year, and plans are in place to scale up," said Norbert Ndjeka, South Africa's director of the drug-resistant tuberculosis programme.
"The drugs are already in a number of our facilities. Definitely these drugs will reach the patients."
The treatment is also being used in Russia and has received conditional guidelines from the World Health Organization (WHO).
But clinical trials aren't concluded, and the drug can be prohibitively expensive—factors that have limited its distribution.
Drug resistance growing
Ndjeka said South Africa was paying approximately $1,000 per six-month course of bedaquiline, which can run a hefty price tag of up to $30,000 in developed countries.
Globally, drug-resistant tuberculosis cases are growing so fast that last year the WHO warned that rates were at "crisis levels."
Tuberculosis, a contagious bacterial infection of the lungs, is one of the world's most deadly diseases, killing 1.5 million people in 2013.
Though promising, experts point out that the new drug is not a silver bullet and has side effects of its own, including liver and heart complications.
"The treatment we've got is not great, but we know what the side effects are," said Andrew Black, a pulmonologist at the University of Witwatersrand in Johannesburg. "At the moment we don't know (enough) about the new drug."
On a Wednesday morning in March, Black was on duty at a drug resistant tuberculosis clinic at the Charlotte Maxeke Johannesburg Academic Hospital.
Over 20 people were waiting for treatment, all with white masks covering their mouths.
Overhead, ultraviolet lights—light kills tuberculosis germs—cast a purple glow on the room. Occasionally, a person let out a hacking cough.
While the new drug is welcome, South Africa's ability to combat tuberculosis is held back by an overstretched health care system, said Black.
People often default in their treatment because they have to travel so far to a clinic and miss countless days of work.
Still, despite the challenges, Black believes South Africa is making progress.
"We won't know if we're winning for a couple of years," he said, "but it's not like HIV was, we're not ignoring it."
Explore further: Turning to freshwater sources to fight drug-resistant tuberculosis, other infections
© 2015 AFP
Medical Xpress on facebook
Related Stories
Turning to freshwater sources to fight drug-resistant tuberculosis, other infections
The discovery of antibiotics produced by soil fungi and bacteria gave the world life-saving medicine. But new antimicrobials from this resource have become scarce as the threat of drug resistance grows. Now, ...
New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency
While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients. New research conducted at the Center for Tuberculosis Research at the Johns Hopkins University ...
Novel treatment for drug-resistant tuberculosis shows promise, but concerns for patient safety remain
In a viewpoint published this week in The Lancet, the Community Research Advisors Group (CRAG) argue that research into bedaquiline – a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) – should procee ...
J&J seeks OK for first drug against resistant TB
(AP) — Johnson & Johnson said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades.
India needs to do much more to tackle its alarming TB epidemic
Effective tuberculosis control in India needs political will and commitment, backed by sufficient resources, says a senior doctor in The BMJ this week.
Recommended for you
Inspection found no problem at Oklahoma ice cream plant
Days after a foodborne illness was linked to Blue Bell ice cream products, a state inspection of an Oklahoma plant later tied to the infection praised the facility for having no violations and doing a "great job," according ...
Bird flu found on at least 15 turkey farms in Midwest
A bird flu strain that's deadly to poultry has been confirmed in a second commercial turkey flock in eastern South Dakota and preliminary tests have confirmed the presence of some form of bird flu at a North Dakota farm, ...
US clinician cured of Ebola, leaves hospital
An American clinician has been cured of Ebola and was discharged from a hospital near the US capital, officials said Thursday.
New high-throughput screening method may uncover novel treatments for kidney disease
A newly developed assay may help investigators identify novel drug candidates to protect kidney cells and prevent or treat chronic kidney disease (CKD). The advance is described in an upcoming issue of the Journal of the Am ...
Early physical therapy for low back pain reduces costs, resources
A study in the scientific journal BMC Health Services Research shows that early and guideline adherent physical therapy following an initial episode of acute, nonspecific low back pain (LBP) resulted in substantially lower ...
New Ebola study points to potential drug target
Opening the door to potential treatments for the deadly Ebola virus, scientists have found that a protein made by the virus plays a role similar to that of a coat-check attendant.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
This photomicrograph reveals Mycobacterium tuberculosis bacteria using acid-fast Ziehl-Neelsen stain; Magnified 1000 X. The acid-fast stains depend on the ability of mycobacteria to retain dye when treated with mineral acid or an acid-alcohol solution such as the Ziehl-Neelsen, or the Kinyoun stains that are carbolfuchsin methods specific for M. tuberculosis. Credit: public domain
Drug-resistant tuberculosis is a major health challenge across much of Africa, but a new medicine being pioneered in South Africa could be a breakthrough after decades of frustration.
Bedaquiline is being made available to 3,000 people suffering side effects of the usual drug-resistant tuberculosis treatment, or who have developed complete drug resistance.
The early signs are encouraging, doctors say, though bedaquiline hasn't yet been tested in large-scale clinical trials.
The new drug—one of the first new tuberculosis antibiotics released in 40 years—was first given to 217 South African patients as part of an early access programme.
Jennifer Hughes, a 36-year-old British doctor in Cape Town, said she has seen the benefits.
Already, word has spread at Hughes's clinic in Khayelitsha, a poor township, and people are coming from all over the city requesting the new drug, developed by US-based pharmaceutical company Janssen.
"Everyone has heard that this is where you get better treatment," said Hughes, who recalls the "really, really happy day" when her first bedaquiline patient was declared tuberculosis-free in November last year.
South Africa has one of the worst tuberculosis epidemics in the world, with more than 1,000 cases per 100,000 people and the department of health describing the rise of drug-resistant tuberculosis as a "major public health problem."
"We want to get 3,000 patients on bedaquiline this year, and plans are in place to scale up," said Norbert Ndjeka, South Africa's director of the drug-resistant tuberculosis programme.
"The drugs are already in a number of our facilities. Definitely these drugs will reach the patients."
The treatment is also being used in Russia and has received conditional guidelines from the World Health Organization (WHO).
But clinical trials aren't concluded, and the drug can be prohibitively expensive—factors that have limited its distribution.
Drug resistance growing
Ndjeka said South Africa was paying approximately $1,000 per six-month course of bedaquiline, which can run a hefty price tag of up to $30,000 in developed countries.
Globally, drug-resistant tuberculosis cases are growing so fast that last year the WHO warned that rates were at "crisis levels."
Tuberculosis, a contagious bacterial infection of the lungs, is one of the world's most deadly diseases, killing 1.5 million people in 2013.
Though promising, experts point out that the new drug is not a silver bullet and has side effects of its own, including liver and heart complications.
"The treatment we've got is not great, but we know what the side effects are," said Andrew Black, a pulmonologist at the University of Witwatersrand in Johannesburg. "At the moment we don't know (enough) about the new drug."
On a Wednesday morning in March, Black was on duty at a drug resistant tuberculosis clinic at the Charlotte Maxeke Johannesburg Academic Hospital.
Over 20 people were waiting for treatment, all with white masks covering their mouths.
Overhead, ultraviolet lights—light kills tuberculosis germs—cast a purple glow on the room. Occasionally, a person let out a hacking cough.
While the new drug is welcome, South Africa's ability to combat tuberculosis is held back by an overstretched health care system, said Black.
People often default in their treatment because they have to travel so far to a clinic and miss countless days of work.
Still, despite the challenges, Black believes South Africa is making progress.
"We won't know if we're winning for a couple of years," he said, "but it's not like HIV was, we're not ignoring it."
Explore further: Turning to freshwater sources to fight drug-resistant tuberculosis, other infections
© 2015 AFP
Medical Xpress on facebook
Related Stories
Turning to freshwater sources to fight drug-resistant tuberculosis, other infections
The discovery of antibiotics produced by soil fungi and bacteria gave the world life-saving medicine. But new antimicrobials from this resource have become scarce as the threat of drug resistance grows. Now, ...
New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency
While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients. New research conducted at the Center for Tuberculosis Research at the Johns Hopkins University ...
Novel treatment for drug-resistant tuberculosis shows promise, but concerns for patient safety remain
In a viewpoint published this week in The Lancet, the Community Research Advisors Group (CRAG) argue that research into bedaquiline – a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) – should procee ...
J&J seeks OK for first drug against resistant TB
(AP) — Johnson & Johnson said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades.
India needs to do much more to tackle its alarming TB epidemic
Effective tuberculosis control in India needs political will and commitment, backed by sufficient resources, says a senior doctor in The BMJ this week.
Recommended for you
Inspection found no problem at Oklahoma ice cream plant
Days after a foodborne illness was linked to Blue Bell ice cream products, a state inspection of an Oklahoma plant later tied to the infection praised the facility for having no violations and doing a "great job," according ...
Bird flu found on at least 15 turkey farms in Midwest
A bird flu strain that's deadly to poultry has been confirmed in a second commercial turkey flock in eastern South Dakota and preliminary tests have confirmed the presence of some form of bird flu at a North Dakota farm, ...
US clinician cured of Ebola, leaves hospital
An American clinician has been cured of Ebola and was discharged from a hospital near the US capital, officials said Thursday.
New high-throughput screening method may uncover novel treatments for kidney disease
A newly developed assay may help investigators identify novel drug candidates to protect kidney cells and prevent or treat chronic kidney disease (CKD). The advance is described in an upcoming issue of the Journal of the Am ...
Early physical therapy for low back pain reduces costs, resources
A study in the scientific journal BMC Health Services Research shows that early and guideline adherent physical therapy following an initial episode of acute, nonspecific low back pain (LBP) resulted in substantially lower ...
New Ebola study points to potential drug target
Opening the door to potential treatments for the deadly Ebola virus, scientists have found that a protein made by the virus plays a role similar to that of a coat-check attendant.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment